期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

成本效果阈值理论介绍:单位、定义与特征 被引量：5

Introduction of Cost-effectiveness Threshold Value: Unit,Definition and Characteristic
原文传递
导出
摘要 目前,成本效果阈值的单位、定义与特征存在着诸多争议,经过分析比较将这些争议与不同详细列出,并简要分析其优缺点,为我国成本效果阈值的单位、定义与特征的确立奠定基础。 Nowadays, the concept of cost-effeetiveness threshold value has a lot of arguments, The paper lists these arguments, has a comparison between them, and briefly analyzes their advantages and disadvantages to lay a foundation for the identification of costeffectiveness threshold value concept.
作者 宗欣 孙利华
机构地区 沈阳药科大学工商管理学院
出处 《中国卫生经济》 北大核心 2012年第3期65-67,共3页 Chinese Health Economics
关键词 成本效果阈值 增量成本效果比 质量调整生命年 获得的生命年 cost-effectiveness threshold value ICER QALY LYG
分类号 R95 [医药卫生—药学] F203 [经济管理—国民经济]
  • 相关文献

参考文献9

  • 1李海涛,李士雪,夏慧,李士保.药物经济学评价在国际卫生决策领域的应用现状、问题与对策[J].中国卫生经济,2006,25(9):75-78. 被引量：9
  • 2马进,蒋飞.第一讲 经济学评价概述(一)[J].中国卫生经济,2002,21(3):58-59. 被引量：5
  • 3World Health Organization.WHO-CHOICE[EB/OL].[2011-06-08].http://www.who.int/choice/costs/CERthresholds/en/index.html.
  • 4Milton C W,George T,Alistair M.QALYs:the basics[J].Value in health,2009,12(Suppl.1):S5-S9.
  • 5Appleby J,Devlin N,Parkin D,et al.Searching for cost effec-tiveness thresholds in the NHS[J].Health Policy,2009,91(3):239-245.
  • 6Weinstein M,Zeckhauser R.Critical ratios and efficient allo-cation[J].Journal of Public Economics,1973,2(2):147-157.
  • 7Health Economic Glossary[EB/OL].[2011-12-25].http://www.healtheconomics.nl/W/Cost-effectiveness_threshold.
  • 8National Institute for Health and Clinical Excellence.Guide to the methods of technology appraisal(2008)[EB/OL].[2010-06-08].http://www.nice.org.uk/aboutnice/howwework/devnicetech/technologyappraisalprocessguides/guidetothemetho dsoftechnologyappraisal.jsp.
  • 9Devlin N,Parkin D.Does NICE have a cost-effctiveness thre-shold and what other factors influence its decisions?A binary choice analysis[J].Health Economics,2004,13(5):437-452.

二级参考文献23

  • 1Commonwealth Department of Human Services. Guidelines for the Pharmaceutical Industry on Preparation of Submissions to the Pharmaceutical Benefits Advisory Committee Including Major Submissions Involving Economic Analyses[S]. Canberra: Australian Government Publishing Service, 1995.
  • 2Henry·D, Lopert·R. Pharmacoeconomics' and Policy Decisions: the Australian Health Care System[J]. Clin Therap, 1999,21(2):909-915.
  • 3Kanavos, P. Pharmaceutical Pricing and Reimbursement in Europe -2002[S]. PJB Publications Ltd. 2002.
  • 4National Institute for Clinical Excellence. Technical Guidance for Manufacturers and Sponsors on Making a Submission to a Technology Appraisal[S]. March , 2001.
  • 5Torrance·G. Current Experience With Guidelines for Economic Evaluation in Canada[J]. Drug Inf J, 1996(30):507-511.
  • 6Glennie ·J.L, Torrance ·G ·W, Baladi·J·F , et al . The revised Canadian Guidelines for the Economic Evaluation of Pharmaceuticals[J]. Pharmacoeconomics , 1999, 15(5):459.
  • 7Anis ·A.H, Gagnon Y. Using Economic Evaluations to Make Formulary Coverage Decisions : So Much for Guidelines [J].Pharmacoeconomics, 2000, 18(1):55 -62.
  • 8Rameckers E. Using Health Outcomes Data to Inform Decision-making: Patient Perspective[J]. Pharmacoeconomics, 2001, 19(2):53-55.
  • 9Luce·B.R. Cost-effectiveness Analysis-obstacles to Standardisation and its use in Regulating Pharmaceuticals[J]. Pharmacoeconomics,1993, 3(1):1-9.
  • 10Martin·P.A. Writing a Useful Literature Review for a Quantitative Research Project[J]. Appl Nurs Res, 1997, 10(3):159-162.

共引文献12

同被引文献24

  • 1刘柏,赵振全,汪玲丽,刘周楠.卫生经济成本效果分析的前沿评价方法研究[J].中国卫生经济,2006,25(6):75-76. 被引量：13
  • 2Rikke Soegaard,Cody E. Bünger,Terkel Christiansen,Finn B. Christensen.Determinants of cost-effectiveness in lumbar spinal fusion using the net benefit framework: a 2-year follow-up study among 695 patients[J]. European Spine Journal . 2007 (11)
  • 3Andrew R.Willan,Andrew H.Briggs,Jeffrey S.Hoch.Regression methods for covariate adjustment and subgroup analysis for non‐censored cost‐effectiveness data[J]. Health Econ. . 2004 (5)
  • 4Kobelt G,Eberhardt K,Geborek P.TNF inhibitors in the treatment of rheumatoid arthritis in clinical practice: costs and outcomes in a follow up study of patients with RA treated with etanercept or infliximab in southern Sweden. Annals of the Rheumatic Diseases . 2004
  • 5Hoch Jeffrey,Rockx Marie,Krahn Andrew.Using the net benefit regression framework to construct cost-effectiveness acceptability curves: an example using data from a trial of external loop recorders versus Holter monitoring for ambulatory monitoring of "community acquired" syncope. BMC Health Services Research . 2006
  • 6Stinnett A A,Mullahy J.Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis. Medical decision making : an international journal of the Society for Medical Decision Making . 1998
  • 7Magnus Tambour,Niklas Zethraeus,Magnus Johannesson.A Note on Confidence Intervals in Cost-Effectiveness Analysis. International Journal of Technology Assessment in Health Care . 1998
  • 8Sennen Hounton,David Newlands.Applying the net-benefit framework for assessing cost-effectiveness of interventions towards universal health coverage. Cost Effectiveness and Resource Allocation . 2012
  • 9National Institute for Health and Clinical Excellence.Guide to guithe methods of technology appraisal. http://www.nice.org.uk/media/B52/A7/TAMethodsGuideUpdatedJune2008 .pdf . 2008
  • 10Hoch Jeffrey S,Briggs Andrew H,Willan Andrew R.Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. Journal of Health Economics . 2002

引证文献5

二级引证文献17

中国卫生经济
2012年 第3期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部